参芪地黄汤加减治疗2型糖尿病合并膜性肾病30例临床观察.pdf

《参芪地黄汤加减治疗2型糖尿病合并膜性肾病30例临床观察.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、1332阿北中医2014年9月第36卷第9期HebeiJTCM，September2014，Vol36⋯No．9．毫：蠹嚣薯：要-瓤：：：至薹誊-。一=：薯萼彗×誊。．杀蠹：参芪地黄汤加减治疗2型糖尿病合并膜性肾病3O例临床观察※孔令新王艳云田朝阳李莉(北京市房山区中医医院肾病科，北京102400)【摘要】目的观察参芪地黄汤加减治疗2型糖尿病合并膜性肾病临床疗效。方法将60例2型糖尿病合并膜性肾病患者随机分为2组。对照组3O例予西医常规治疗，治疗组30例在对照组治疗基础上加用参芪地黄汤加减治疗。

2、2组均3个月为1个疗程，1个疗程后统计疗效，并观察2组治疗前后中医证候积分、24h尿蛋白定量(24Upro)、血清白蛋白(Alb)、血清肌酐(Cr)、糖化血红蛋白(HbAlc)及总胆固醇(Tc)。结果2组中医、西医总有效率比较差异均有统计学意义(P<0．05)，治疗组疗效优于对照组。2组治疗后中医证候积分、24Upro均降低(P<0．05)，且治疗组降低优于对照组(P<0．05)；2组治疗后Alh均升高(P<0．05)，且治疗组升高优于对照组(P<0．05)。2组治疗后Cr、HbAlc及TC与本

3、组治疗前及组间比较差异无统计学意义(P>0．05)。结论参芪地黄汤加减治疗2型糖尿病合并膜性肾病疗效确切。【关键词】糖尿病；并发症；肾小球肾炎，膜性；中药疗法【中图分类号】R280．5；~．115．31；RID2．310．531【文献标识码】A【文章编号】11312—2619(2014)09—1332—04InvestigationofSbenqiDihuangdecoctiononthetreatmentoftype2diabeteswithmembranousnephropathyKONGL

4、ingxin，WANGYanyun，TIANZhaoyang，eta1．DivisionofNephrosis，FangshanDistrictHospitalofTraditionalChineseMedicineinBeng，Beng102400【Abstract】ObjectiveToinvestigatetheclinicaleffectofShenqiDihuangdecoctionO1"1thetreatmentoftype2diabeteswithmembranousnephrop

5、athy．Methods60casesoftype2diabeteswithmembranousnephropathywererandomlydividedintotwogroups．Patientsincontrolgroup(n=30)weretreatedbywesternconventionaltreatment．Patientsintreatmentgroup(n=30)weretreatedbyShenqiDihuangdecoctionOilthebasisofcontrolgro

6、uptreat—ment．nlecoursewasthreemonthsintwogroups．Thetherapeuticeffectwasevaluatedafteracourse．TCMscore．24Upro，Alb，Cr，HbAlcandTCinserumwereobservedbeforeandaftertreatmentintwogroups．ResultsTherewassignificantdiferencebetweenwesternmedicineandtraditiona

7、lChinesemedicineonthetotalefectiverateintwogroups(P<0．05)．Thetherapeuticefectintreatmentgroupwassuperiortothatincontrolgroup．TCMscoreand24Uproaftertreatmentweredecreasedintwogroups(P<0．05)．Thedecreaseintreatmentgroupwassuperiortothatincontrolgroup(P<

8、0．05)．Albaftertreatmentwereincreasedintwogroups(P<0．05)．rheincreaseintreatmentgroupwassuperiortothatincontrolgroup(P<0．05)．TherewasnosignificantdifferencebetweenbeforeandaftertreatmentonCr，HbAlcandAlbintwogroups(P>0．05)．ConclusionShenqiDihuangdecocti